J&J, Actelion Tentatively Agree on Price

Jan 12, 2017

Bloomberg

According to a Bloomberg article, Johnson & Johnson has tentatively agreed with Actelion Ltd. on a price to acquire the biotechnology company, said people familiar with the matter. Discussions are focused on valuing what would be a new unit that would house the research and development assets.

As previously reported, Actelion’s R&D would be spun off into a new company and its shareholders would be able to keep some stock in that business, sources said. Before the latest negotiations started in late December, J&J had made an offer for Actelion valued at more than $28 billion.

Read the Bloomberg article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments